Search
Showing results for "1"
Research
Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?Streptococcus pyogenes is commonly believed to be resistant to trimethoprim-sulfamethoxazole (SXT), resulting in reservations about using SXT for skin and...
Research
Colostrum as a Protective Factor Against Peanut Allergy: Evidence From a Birth CohortFood allergy affects families' quality of life, can be lifelong and life-threatening, urging the identification of early modifiable risk factors. Formula feeding in the first days of life may increase the risk of cow's milk allergy, a risk often attributed to cow's milk allergens exposure. Early formula feeding also reduces the colostrum intake, the first 3 days' milk, which is rich in bioactive compounds critical for immune and gut health. This study investigates whether partial colostrum feeding increases the risk of food allergy beyond cow's milk.
Research
Incidence of acute rheumatic fever in northern and western Uganda: a prospective, population-based studyAcute rheumatic fever is infrequently diagnosed in sub-Saharan African countries despite the high prevalence of rheumatic heart disease. We aimed to determine the incidence of acute rheumatic fever in northern and western Uganda.
Research
Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastomaMedulloblastoma (MB) consists of four core molecular subgroups with distinct clinical features and prognoses. Treatment consists of surgery, followed by radiotherapy and cytotoxic chemotherapy. Despite this intensive approach, outcome remains dismal for patients with certain subtypes of MB, namely, MYC-amplified Group 3 and TP53-mutated SHH. Using high-throughput assays, six human MB cell lines were screened against a library of 3208 unique compounds. We identified 45 effective compounds from the screen and found that cell cycle checkpoint kinase (CHK1/2) inhibition synergistically enhanced the cytotoxic activity of clinically used chemotherapeutics cyclophosphamide, cisplatin, and gemcitabine.
News & Events
Crucial advancement in the treatment of childhood sarcomaCure Cancer and The Kids Research Institute Australia researcher Dr Ben Wylie announced new potential treatment in time for Childhood Sarcoma Awareness month.
News & Events
PhD pathway program ensuring bright future for clinical research in WATwo outstanding Perth Children’s Hospital clinicians will be supported to pursue a career in medical research, paving the way for more clinician-scientists in Western Australia.
News & Events
Ideas Grants to support innovative researchTwo research teams, led by The Kids Research Institute Australia, have been awarded more than $2 million to fund innovative projects.
News & Events
The Kids infectious diseases researcher named a WA Young Tall PoppyA The Kids researcher focused on ensuring kids are protected from infectious diseases will be named among WA’s most outstanding young scientists at the upcoming 2021 Young Tall Poppy Science Awards.
News & Events
Researchers to focus on MS inflammation puzzleThe Kids Research Institute Australia researchers will seek to better understand the relationship between antibodies and inflammation in people with multiple sclerosis (MS), thanks to a generous grant from MS Research Australia.
News & Events
The Kids Research Institute Australia researchers share in TPCHRF fundingEight The Kids Research Institute Australia researchers are among those who have received grant funding from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).